Related Experiment Video

Updated: Jun 22, 2026

New Tools to Expand Regulatory T Cells from HIV-1-infected Individuals
09:27

New Tools to Expand Regulatory T Cells from HIV-1-infected Individuals

Published on: May 30, 2013

Pediatric HIV: new opportunities to treat children

Dimitri Van der Linden1, Steven Callens, Bénédicte Brichard

  • 1Cliniques Universitaires UCL St Luc, Pediatrics Department, 10 Avenue Hippocrate, 1200 Brussels, Belgium. dimitri.vanderlinden@uclouvain.be

Expert Opinion on Pharmacotherapy
|June 30, 2009
PubMed

Insights

Improving pediatric HIV treatment requires addressing limited drug options and formulations. New guidelines recommend early antiretroviral therapy for infants, but access and palatability remain challenges, especially in resource-limited settings.

Area of Science:

  • Pediatric Infectious Diseases
  • HIV/AIDS Treatment
  • Global Health

Background:

  • Treating HIV in children is challenging due to limited treatment options and formulations.
  • Access to diagnostics and treatment for pediatric HIV is insufficient in resource-limited settings.

Purpose of the Study:

  • To review current data on new opportunities for improving HIV treatment in children.
  • To highlight advancements and persistent challenges in pediatric antiretroviral therapy.

Main Methods:

  • Comprehensive review of recent peer-reviewed publications.
  • Analysis of current international treatment guidelines.
  • Inclusion of data from major international meetings on pediatric HIV.

Main Results:

  • New WHO guidelines advocate for initiating combination antiretroviral treatment in all infants under one year old.
  • Implementation of these guidelines faces significant challenges in resource-limited countries.
  • A notable disparity exists in licensed drug availability for children compared to adults.

Conclusions:

  • Further pharmacokinetic studies are essential for optimizing pediatric HIV treatment.
  • Development of more palatable pediatric formulations of antiretroviral drugs is critically needed.
  • Bridging the gap in pediatric drug availability and access is crucial for global HIV control in children.
Abstract

More Related Videos

Expanding Cytotoxic T Lymphocytes from Umbilical Cord Blood that Target Cytomegalovirus, Epstein-Barr Virus, and Adenovirus11:18

Expanding Cytotoxic T Lymphocytes from Umbilical Cord Blood that Target Cytomegalovirus, Epstein-Barr Virus, and Adenovirus

Published on: May 7, 2012

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice06:07

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice

Published on: October 6, 2022

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...